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Objective: This study aimed to investigate clinical factors affecting the concordance between frozen
section (FS) and parafﬁn section (PS) ﬁndings in endometrial cancer, and evaluate the role of FS in
predicting lymph node (LN) metastases.
Methods: Tumor grade and depth of myometrial invasion based on FS and PS ﬁndings were compared in
376 patients. Clinical factors affecting the accuracy of FS in predicting LN metastasis were evaluated.
Overall survival was compared between patients who underwent lymphadenectomy and those who did
not.
Results: Overall concordance of tumor grade was 78.6% (147/187). Later age at menopause (p ¼ 0.011)
and a lower systolic/diastolic ratio of endometrial blood ﬂow (p ¼ 0.015) were associated with high
concordance between FS and PS for tumor grade. Overall concordance for the depth of myometrial in-
vasion was 97.8% (178/182). There was greater concordance between FS and PS for myometrial invasion
in patients with postmenopausal bleeding (p ¼ 0.018) and lower abdominal pain (p ¼ 0.013). G1 and
G2 þ no myometrial invasion predicted no metastasis; G1 þ <1/2 myometrial invasion predicted a 2.4%
risk of both pelvic LN and para-aortic LN metastasis. G2 þ <1/2 myometrial invasion predicted a 4.8% risk
of pelvic LN metastasis. Patients undergoing lymphadenectomy showed relatively longer survival than
those without lymphadenectomy (p ¼ 0.086).
Conclusion: The accuracy of FS in determining tumor grade and myometrial invasion appears to be
reliable. LN metastases cannot be predicted adequately by intraoperative FS. We recommend complete
surgical staging for all patients with endometrial cancer.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Endometrial cancer is one of the most common malignancies of
the female genital tract, and its incidence in China is similar to that
reported in the United States.1 Comprehensive surgical staging is
the cornerstone of management in endometrial cancer.2 Pathology
results, including preoperative endometrial biopsy, intraoperative
frozen section (FS), and postoperative parafﬁn section (PS), are used
to determine the management of endometrial cancer at three
stages. Preoperative assessments consist of endometrial biopsy,
fractional dilation and curettage (D&C), and hysteroscopy, and
provide an initial diagnosis to clinicians. However, pathologic, Shanghai First Maternity &
, China.
ng).
for Gynecologic Endoscopy and Minimﬁndings obtained from preoperative intervention often differ from
the ﬁnal pathology.3e5 Our previous study showed that the overall
concordance between D&C and ﬁnal pathology was only 35.2% (62/
176) for tumor grade.3 Intraoperative FS can detect the tumor grade,
depth of myometrial invasion, histologic subtype, and cervical
extension of the tumor. During surgery, FS is the only way to
identify the subgroup of patients who have a high risk of extra-
uterine metastases and to direct comprehensive surgical staging.
Postmenopausal bleeding is the initial symptom in most endo-
metrial cancer patients. Thus, approximately 75% of all cases un-
dergoing endometrial biopsy are diagnosed at early Stage I and
have an excellent prognosis. The overall 5-year survival rate is
80e90%.6,7 The Gynecologic Oncology Group (GOG-33) study
veriﬁed that the incidence of lymph node metastasis is very low in
most of the early-stage endometrial cancers.6 Although lymph
node involvement has been proved to be the most signiﬁcant
prognostic factor, the role of lymphadenectomy in the surgicalally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Comparison of tumor grade between intraoperative frozen section and post-
operative parafﬁn section [n (%)].
Frozen
section
Parafﬁn section
Atypia G1 G2 G3 Total
Atypia 6 (85.7) 8 (9.1) 3 (4.2) 0 17 (9.1)
G1 0 78 (88.6) 20 (28.2) 0 98 (52.4)
G2 0 1 (1.1) 43 (60.6) 1 (4.8) 45 (24.1)
G3 1 (14.3) 1 (1.1) 5 (7.0) 20 (95.2) 27 (14.4)
Total 7 (100.0) 88 (100.0) 71 (100.0) 21 (100.0) 187 (100.0)
G ¼ grade; n ¼ number of patients.
Y. Wu et al. / Gynecology and Minimally Invasive Therapy 4 (2015) 126e131 127management of early-stage endometrial cancer remains contro-
versial.8 The issue is whether or not lymph node invasion can be
predicted pre- or intraoperatively. When a “high risk” of lymph
node metastases is detected, comprehensive surgical staging
should be performed; otherwise, lymphadenectomy may be
omitted. The risk of lymph node metastasis is directly related to
high grade of tumor and deeper invasion into the myometrium.
In this study, we retrospectively compared the results of intra-
operative FS and postoperative PS, and explored clinical factors
affecting the concordance between FS and ﬁnal pathology. The role
of FS in predicting lymph node metastases was also evaluated.
Materials and methods
Medical documents for 389 patients with abnormal uterine
bleeding, who underwent D&C or hysteroscopy from July 1996 to
January 2008 at Renji Hospital afﬁliated to Shanghai Jiao Tong
University (n ¼ 170) and from September 2008 to September 2011
at Shanghai First Maternity & Infant Hospital afﬁliated to Tongji
University (n ¼ 219), were reviewed retrospectively. Patients who
had undergone previous pelvic radiation or had clinically advanced
disease, coexisting second malignancy, and uterine sarcoma were
excluded. This study was approved by the institutional review
board of both the universities.
The indication for surgical treatment was endometrial cancer or
complex endometrial hyperplasia with atypia. A total of 376 pa-
tients were managed by surgery, and FS was performed in 220 of
them. The primary surgical procedure was total or radical hyster-
ectomy and bilateral salpingo-oophorectomy. When the uterus was
removed, the surgeons observed the dimension of foci and depth of
myometrial invasion, and then the uterus was submitted to the
Department of Pathology for FS assessment. The uterus was
bivalved, and the endomyometrium was sliced transversely at
4e5 mm intervals. One full-thickness section of the endometrial
wall at the point of deepest invasionwas submitted for microscopic
examination. Sections of 5 mmwere cut by a Cryotome E (Artmoor,
Runcorn, UK), mounted on a glass slide, stained with hematox-
ylineeosin, and dehydrated. Full thickness was evaluated on one
slide, and cervical involvement was evaluated on another slide. The
sections weremicroscopically evaluated by two pathologists within
30 minutes.
Based on FS results, patients considered to be at risk of meta-
static disease, such as Grade 3 tumor or >1/2 myometrial invasion,
underwent lymph node dissection.
Statistical analysis
The ManneWhitney test and c2 tests were used for categorical
variables and the likelihood ratio calculation, respectively. A two-
tailed Student t test was used to calculate the means of contin-
uous variables. A value of p < 0.05 was considered statistically
signiﬁcant. KaplaneMeier survival analysis was used to measure
overall survival of patients with or without lymph node dissection.
Those statistical analyses were processed with SPSS statistical
software version 15.0 (SPSS, Inc., Chicago, IL, USA).
Results
Among 389 patients, 327 were diagnosed to have endometrial
cancer or complex atypical endometrial hyperplasia by D&C and 50
were diagnosed by hysteroscopy preoperatively. The mean age of
the 389 patients was 57.74 ± 9.52 years (range 26e85 years), the
mean age of menarche was 14.99 ± 1.59 years, and 232 had un-
dergone menopause at a mean age of 51.06 ± 4.16 years. The pre-
senting symptoms in these 389 patients were as follows:postmenopausal bleeding in 232 patients (59.6%), which occurred
at a median time of 108.4 months after menopause; abnormal
perimenopausal bleeding in 11 patients (2.8%); menstrual disor-
ders, including irregular menstrual cycle, prolonged bleeding, and
menorrhagia in 95 patients (24.4%); and profuse vaginal discharge
in 60 patients (15.4%). The other 51 patients (13.1%) were asymp-
tomatic, but endometrial thickening and intrauterine neoplasm
were detected by B ultrasound.
A total of 376 patients underwent radical hysterectomy and
bilateral salpingo-oophorectomy, with pelvic lymph node dissec-
tion in 197 patients or simultaneously with para-aortic lymph node
dissection in 41 (43) patients. It was found that 266 patients (70.7%)
in IA, 39 patients (10.4%) in IB, 22 patients (5.9%) in IIA, six patients
(1.6%) in IIB, 10 patients (2.7%) in IIIA, two patients (0.5%) in IIIB, 17
patients (4.5%) in IIIC, one patient (0.3%) in IVA, and 13 patients
(3.5%) in IVB were based on FIGO 2009 surgical staging system. In
all, 345 (90.3%) patients had type I adenocarcinoma; the other 37
patients had type II endometrial carcinoma, including 24 patients
with papillary serous carcinoma, six with clear cell carcinoma, ﬁve
with adenosquamous carcinoma, and two with squamous carci-
noma. Among 197 patients undergoing lymph node resection, 22
(11.3%) presented with pelvic lymph node metastasis and ﬁve
(12.2%) with para-aortic lymph node metastasis.Comparison of tumor grade between FS and PS
Table 1 summarizes the results of histologic grade concordance
between FS and PS. Among the patients in whom the ﬁnal patho-
logic diagnosis was endometrial cancer or atypia, the overall
concordance rate of tumor grade was 78.6% (147/187). Accuracy
was highest for Grade 3 (95.2%) and lowest for Grade 2 (60.6%).
Based on the ﬁnal pathology, a total of 32 patients (17.1%) were
upgraded and eight (4.3%) downgraded.Comparison of depth of myometrial invasion between FS and PS
Myometrial invasion was assessed in 182 patients (Table 2). The
overall concordance between intraoperative FS and PS was 97.8%
(178/182). Among the 182 cases, only four showed discordance.
These ﬁndings suggest that FS was reliable for the assessment of
tumor invasion.
Histologic grade and depth of myometrial invasion were
believed to be the most important prognostic factors for lymph
node metastasis. Table 3 shows the correlation between tumor
grade and depth of myometrial invasion. Among the patients with
1/2 myometrial invasion, the total percentage of Grade 2 and 3
tumors was 75.3%, and the percentage of Grade 1 was 24.7%. In
cases with <1/2 invasion, the percentage of Grade 3 was only 10.5%.
Thus, a poorly differentiated tumor grade implied aggressive tumor
invasion into the myometrium.
Table 2
Comparison of myometrial invasion between intraoperative frozen section and
postoperative parafﬁn section [n (%)].
Parafﬁn section
Frozen section <1/2 1/2 Total
<1/2 144 (99.3) 3 (8.1) 147 (80.8)
1/2 1 (0.7) 34 (91.9) 35 (19.2)
Total 145 (100.0) 37 (100.0) 182 (100.0)
Table 3
Correlation of tumor grade and myometrial invasion [n (%)].
Tumor grade Myometrial invasion
<1/2 1/2 Total
G1 114 (44.2) 18 (24.7) 132 (39.9)
G2 117 (45.3) 32 (43.8) 149 (45.0)
G3 27 (10.5) 23 (31.5) 50 (15.1)
Total 262 (100.0) 74 (100.0) 336 (100.0)
Table 4
Comparison of clinical factors between concordance and discordance groups (%).
Tumor grade Myometrial invasion
Concordance Discordance Concordance Discordance
Age (y)
<70 133 (67.9) 63 (32.1) 155 (96.9) 5 (3.1)
70 19 (82.6) 4 (17.4) 22 (100.0) 0 (0.0)
p 0.230 0.521
Postmenopausal bleeding
Yes 87 (73.7) 31 (26.3) 99 (100.0) 0 (0.0)
No 65 (64.4) 36 (35.6) 78 (94.0) 5 (6.0)
p 0.144 0.018
Lower abdominal pain
Yes 17 (68.0) 8 (32.0) 19 (86.4) 3 (13.6)
No 135 (69.6) 59 (30.4) 158 (98.8) 2 (1.2)
p 0.518 0.013
Vaginal discharge
Yes 136 (69.7) 59 (30.3) 155 (98.1) 3 (1.9)
No 16 (66.7) 8 (33.3) 22 (91.7) 2 (8.3)
p 0.815 0.130
Neoplasm dimension
<25 mm 34 (65.4) 18 (34.6) 42 (95.5) 2 (4.5)
25 mm 21 (77.8) 6 (22.2) 24 (96.0) 1 (4.0)
p 0.309 0.704
RI
<0.5 24 (80.0) 6 (20.0) 24 (88.9) 3 (11.1)
0.5 20 (60.6) 13 (39.4) 31 (96.9) 1 (3.1)
p 0.108 0.323
Histologic type
Ⅰ 142 (71.4) 57 (28.6) 161 (97.0) 5 (3.0)
Ⅱ 9 (50.0) 9 (50.0) 15 (100.0) 0 (0.0)
p 0.067 0.646
Cervical involvement
Yes 24 (77.4) 7 (22.6) 29 (96.7) 1 (3.3)
No 127 (67.9) 60 (32.1) 148 (97.4) 4 (3.6)
p 0.401 0.598
Lymph node number
<20 61 (74.4) 21 (25.6) 72 (94.7) 4 (5.3)
20 46 (70.8) 19 (29.2) 56 (98.2) 1 (1.8)
p 0.710 0.391
Gross depth of invasion
No 3 (33.3) 6 (66.7) 8 (100.0) 0 (0.0)
<1/2 13 (76.5) 4 (23.5) 13 (92.9) 1 (7.1)
1/2 12 (92.3) 1 (7.7) 12 (100.0) 0 (0.0)
p 0.013* >0.99
Tumor grade
Atypia 6 (46.2) 7 (53.8) 4 (100.0) 0 (0.0)
G1 75 (78.1) 21 (21.9) 83 (98.8) 1 (1.2)
G2 42 (60.0) 28 (40.0) 66 (98.5) 1 (1.5)
G3 19 (82.6) 4 (17.4) 17 (85.0) 3 (15.0)
p 0.008* 0.027
Myometrial invasion
<1/2 98 (76.0) 31 (24.0) 143 (98.6) 2 (1.4)
1/2 30 (76.9) 9 (23.1) 34 (91.9) 3 (8.1)
p 0.002* 0.058
ER
Positive 39 (69.6) 17 (30.4) 52 (100.0) 0 (0.0)
Negative 11 (78.6) 3 (21.4) 11 (91.7) 1 (8.3)
p 0.742 0.187
PR
Positive 33 (66.0) 17 (34.0) 46 (97.9) 1 (2.1)
Negative 17 (85.0) 3 (15.0) 17 (100.0) 0 (0.0)
p 0.263 1.000
P53
Positive 17 (73.9) 6 (6.1) 21 (100.0) 0 (0.0)
Negative 31 (70.5) 13 (29.5) 38 (97.4) 1 (2.6)
p >0.99 0.650
Outcome
Live 85 (85.9) 32 (82.1) 96 (83.5) 2 (50.0)
Dead 14 (14.1) 7 (17.9) 19 (16.5) 2 (50.0)
P 0.696 0.004
ER ¼ estrogen receptor; PR ¼ progestrone receptor; RI ¼ resistance index.
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According to concordance of histologic grade and depth of
myometrial invasion between FS and PS, patients were divided into
concordance and discordance groups. More than 50 clinical factors
were compared, and some with clinical signiﬁcance are shown in
Table 4. The presence of postmenopausal bleeding was related to
higher concordance between FS and PS for myometrial invasion
(p ¼ 0.018). In the comparison of histologic grades between FS and
PS results, the mean age at menopause was 51.7 ± 3.3 years in the
concordance group and 49.3 ± 7.3 years in the discordance group,
which reached a statistical difference (p ¼ 0.011). The systolic/
diastolic ratio of endometrial blood ﬂow was 2.0 ± 0.5 in the
concordance group, which was signiﬁcantly lower than that of
2.3 ± 0.5 in the discordance group (p ¼ 0.015). Apparently, later age
at menopause and a lower systolic/diastolic ratio of endometrial
blood ﬂow were associated with the higher concordance of FS in
tumor grade. Age at menarche, delivery number, endometrial
thickness, and dimension of neoplasm had no effect on the accu-
racy of FS in determining both tumor grade and myometrial
invasion.
Role of FS in predicting lymph node metastasis
Depending on the presence of high-risk factors for lymph node
involvement at intraoperative FS, lymphadenectomy was per-
formed. According to FS results, no positive lymph nodes were
found in patients with atypia. Three (4.8%) of 62 patients with
Grade 1, two (6.9%) of 29 patients with Grade 2, and two (10%) of 20
patients with Grade 3 had nodal metastasis. The incidence of lymph
node metastases was 3.6% (3/81) in patients with <1/2 myometrial
invasion and 12% (3/22) in patients with 50% or more (1/2)
myometrial invasion.
Grade 3 tumor and 1/2 myometrial invasion are considered to
be indicative of a high risk of lymph nodal involvement. The results
of using these two variables, based on FS assessment, to predict
lymph node metastasis are shown in Table 5. The sensitivity was
29.4% for G3 and 15.8% for 1/2 myometrial invasion, with the
corresponding speciﬁcity being 85.8% and 80.5%, respectively.
Intraoperative predictors combining FS assessment of histologic
grade and depth of myometrial invasion were established. Four
models were designed to predict lymph node metastasis, excluding
patients with Grade 3 tumors and 1/2 myometrial invasion. The
incidence of lymph node metastasis by those models is shown in
Table 5
Predictive result on FS.
TP FP TN FN Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
Grade 3 tumor 5 22 133 12 29.4 85.8 18.5 91.7
1/2 myometrial invasion 3 32 132 16 15.8 80.5 9.4 89.2
FN ¼ false negative; FP ¼ false positive; FS ¼ frozen section; NPV ¼ negative predictive value; PPV ¼ positive predictive value; TN ¼ true negative; TP ¼ true positive.
Table 6
Incidence of lymph node metastases by modeled predictor.
Case PLN (þ) PALN (þ)
G1 þ no invasion 4 0 0
G2 þ no invasion 0 0 0
G1 þ <1/2 myometrial invasion 42 1 (2.4%) 1 (2.4%)
G2 þ <1/2 myometrial invasion 21 1 (4.8%) 0
G ¼ grade; PALN ¼ para-aortic lymph node; PLN ¼ pelvic lymph node.
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invasion predictors had no metastases, G1 þ <1/2 myometrial in-
vasion had a 2.4% risk of both pelvic lymph node and para-aortic
lymph node metastasis, and G2 þ <1/2 myometrial invasion had
a 4.8% risk of pelvic lymph node metastasis. Although G1 or G2 and
no myometrial invasion on FS were factors suggesting that lym-
phadenectomy was not necessary, a few of these patients exhibited
lymph node metastasis, emphasizing the necessity of lymph node
dissection.
Survival outcome of patients with or without lymph node dissection
At a median of 412 weeks of follow-up, 196 cases were analyzed.
Nineteen of the 79 patients who did not undergo lymph node
resection died of endometrial cancer, with an overall survival rate
of 75.9%. Twenty-four of the 117 patients who underwent lym-
phadenectomy died as a result of disease progression, with an
overall survival rate of 79.5% (Figure 1). Although there was no
statistically signiﬁcant difference in overall survival between the
two groups (p ¼ 0.086), overall survival was relatively higher in
patients who had undergone lymphadenectomy.
Discussion
The accuracy of intraoperative FS has been discussed extensively
in the literature, and the results are varied. Reported concordance
rates between FS and PS range from68% to 95% for tumor grade,9e13
and from 72% to 95% for depth of myometrial invasion.9,11,12Figure 1. KaplaneMeier analysis of overall survival of patients with or without lymph
node dissection. Cum ¼ cumulative.However, other studies did not ﬁnd high concordance between FS
and PS. Case et al14 carried out a prospective blinded evaluation and
found an accuracy rate of 58% in tumor grade and 67% in depth of
myometrial invasion for FS, which correlated poorly with the ﬁnal
pathology. Papadia et al15 reported that in 16% of 174 cases, FS
underestimated the risk status for lymph node metastasis when
compared with permanent section. Kumar et al8 found that FS re-
sults disagreed with PS results in 35% of cases for the tumor grade,
in 28% for the depth of myometrial invasion, in 13% for cervical
involvement, and in 32% for lymphovascular invasion. In 2009, our
study in 218 patients showed that the concordance rates between
FS for tumor grade and depth of myometrial invasionwere 69% and
87%, respectively.3 In the present study, we reviewed more cases in
order to investigate the accuracy of FS and the clinical factors
affecting it.
In this study, FS was highly accurate for determining the depth
of myometrial invasion that the overall concordance ratewas 97.8%,
which is higher than those reported in previous studies. This
ﬁnding might be due to processing of more FSs in our pathology
department. Nowadays, pathologists always make two to four
sections for FS diagnosis. It was reported that with a minimum of
four transverse sections, the accuracy of FS for myometrial invasion
was 95%,10,16 while with only one to two sections, the accuracy was
72%.11,17When tumor inﬁltration into themyometriumwas obvious
to the pathologists, the deepest invasive site could be identiﬁed. If
not, FSs were made at random, thus increasing the possibility of
missing the area of myometrial invasion.
Intraoperative FS was correlated with PS for tumor grade in
78.6% of cases in our study. Some authors feel that determining
whether solid nonsquamous growth comprises less than or greater
than 5% of the tumor is often problematic and arbitrary.18 In a
retrospective review, Scholten et al19 found a shift from Grade 2 to
Grade 1 in 78% of cases that were originally Grade 2. Similarly,
lower concordance of Grade 2 was observed in our study when
compared with Grades 1 and 3. In an environment cold enough for
FS, a cell may be enlarged or damaged as a result of ice formation
inside the cell, making it difﬁcult for a pathologist to determine the
exact tumor grade. We found that the concordance rate for Grade 3
disease was highest, partly because Grade 3 tumor could contain
Grade 1 and 2 tumor tissue.When Grade 3 tissuewas identiﬁed, the
diagnosis of Grade 3 disease was deﬁnitive; when Grade 3 tissue
was not obtained, the patient could be downgraded on the basis of
FS assessment. In our study, 32 (17.1%) patients were upgraded on
the ﬁnal pathology, while only eight (4.3%) were downgraded. In
the 32 cases diagnosed with normal, simple hyperplasia, or com-
plex hyperplasia on FS, the histologic grade rose in 20 cases, of
which 12 were found to have endometrial carcinoma on the ﬁnal
pathology.
Postmenopausal bleeding is the most common primary symp-
tom in endometrial cancer. In our study, more patients with post-
menopausal bleeding and later age at menopause increased the
accuracy of FS in determining the depth of myometrial invasion.
Higher rates of concordance for tumor grade and myometrial in-
vasionwere seen in patients aged 70 years; however, the number
of patients in this age group was small and the results were not
statistically signiﬁcant. Age is believed to be a prognostic factor in
endometrial cancer,20 so older patients and those with later
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can detect the size of the uterus and neoplasm, and the thickness
and blood ﬂow of the endometrium. We found that the size of the
uterus or neoplasm, and the thickness of the endometrium were
not associated with concordance of tumor grade in endometrial
carcinoma. However, a lower systolic/diastolic ratio of blood ﬂow
correlated with a higher concordance rate for tumor grade between
FS and PS. It has been reported that blood ﬂow rates correspond
with increased angiogenesis in endometrial cancers, and might
potentially be used as a good factor for predicting tumor progres-
sion and metastasis in affected women.21,22
In 2006, the American College of Obstetricians and Gynecolo-
gists recommended surgical staging for women with endometrial
cancer, except for those who are young or perimenopausal with
Grade 1 endometrioidal adenocarcinoma associated with atypical
endometrial hyperplasia, and those at an increased risk of mortality
secondary to comorbidities.23 Despite the recommendations of
American College of Obstetricians and Gynecologists, there is still
controversy within our ﬁeld, speciﬁcally with regard to those pa-
tients with the disease appearing to be conﬁned to the uterus.24e26
In the GOG-33 study, patients with Clinical Stage I endometrial
cancer were stratiﬁed into three risk categories. High-risk patients,
deﬁned as having deep myometrial invasion, had an 18% risk of
pelvic node metastasis and a 15% risk of para-aortic lymph node
metastasis. Intermediate-risk patients, deﬁned as having Grade 2 or
3 histology and/or intermediate myometrial invasion, had a 2e6%
risk of nodal metastasis. Low-risk patients with Grade 1 histology
and endometrial involvement only had no lymph node metastasis
in this study.6 Mariani et al27 have suggested that patients with
Grade 1 or 2 endometrioid tumors, with <50% depth of invasion
and <2 cm tumor diameter, or patients with no myometrial inva-
sion regardless of the grade and diameter should not undergo
lymphadenectomy in Mayo clinic practice. In our study, predicting
lymph node metastases at tumor Grade 3 and 1/2 myometrial
invasion as independent factors achieved relatively high speciﬁcity
of 85.8% and 80.8%, respectively. Examinations with high speciﬁcity
are always used to ascertain the diagnosis. Thus, we concluded that
the risk of lymph node metastases is related to a poorly differen-
tiated grade of tumor and deep invasion into the myometrium.
In many institutions, the risk of lymph node metastasis is
modeled from the information obtained by intraoperative FS
combined histologic grade and depth of myometrial invasion, and
then the institutional guidelines regarding surgical management
are established. Patients with Grade 1 or 2, and <1/2 myometrial
invasion are not generally regarded as being in the high-risk sub-
group. Is it reliable to omit lymphadenectomy solely depending on
FS assessment? In our study, for patients who had both an intra-
operative FS revealing Grade 1 or 2 endometrial cancer, and <1/2
myometrial invasion, we constructed four models to predict lymph
node metastasis. Model G1 þ <1/2 myometrial invasion had a 2.4%
risk of both pelvic lymph node and para-aortic lymph node
metastasis, and G2 þ <1/2 myometrial invasion had a 4.8% risk of
pelvic lymph node metastasis. Although the incidence is not high,
based on FS assessment, a percentage of patients will have high-
risk ﬁndings on the ﬁnal pathology that increase their risk of
nodal involvement, but will not have had a lymph node dissection,
and postoperative adjuvant treatment will not be administered
appropriately. These four models were derived from the data re-
ported by Frumovitz et al in 2004.28 They demonstrated that the
G1 þ no invasion predictor had only a 1e2% chance of nodal
metastasis and probably was the only predictor for which one
might decide to forgo lymph node sampling. However, the risk of
lymph node spread of the other three predictors ranged from 2% to
6%. These data indicated that surgeons who use these variables as
the foundation for their decision on whether to sample lymphnodes should perhaps reconsider this approach.28 Papadia et al15
performed a retrospective review in early-stage endometrial can-
cer patients classiﬁed as thosewith low, intermediate, and high risk
for lymph nodal involvement. In 16% of the cases, FS under-
estimated the risk when compared with the permanent section.
They suggested that relying on intraoperative FS to assess the risk
status for lymph node involvement led to suboptimal management
in a substantial number of cases.15
A key issue in deciding whether or not to perform a routine
lymphadenectomy is whether lymphadenectomy improves out-
comes. In our study, after a median follow-up period of 412 weeks,
no statistically signiﬁcant difference was found in overall survival
between patients who underwent lymph node resection and those
who did not (p ¼ 0.086). However, overall survival in patients with
lymphadenectomy was relatively longer than in patients without
lymphadenectomy. Multiple studies evaluating this issue have re-
ported contradictory results. Some authors have reported that
among patients with intermediate- or high-risk disease charac-
teristics, there was a survival advantage in those who underwent
lymph node resection.29e32 In contrast, others concluded that there
was no statistically signiﬁcant difference in disease-free and overall
survival between patients who underwent lymphadenectomy and
who did not,33 and only a small portion of patients would have
beneﬁted from routine lymphadenectomy.34e36 It is difﬁcult to
make any deﬁnitive conclusion about the therapeutic role of lym-
phadenectomy from retrospective studies.
In summary, it was concluded that the determination of depth of
myometrial invasion by FS was highly accurate; however, the ac-
curacy of FS in determining tumor grade was less reliable. Relying
on FS to tailor lymphadenectomy might lead to suboptimal man-
agement. Therefore, gynecologic oncologists have to be cautious
when using FS assessment to determine the extent of operation.
This is the reason we support full staging for all patients with
endometrial cancer until a better method for predicting lymph
node metastasis can be validated.
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